Antineutrophil cytoplasmic antibody associated vasculitides with renal involvement:Open challenges in the remission induction therapy

• 作者: Aris Tsalouchos Maurizio Salvadori
• 来源期刊: 世界肾病学杂志：英文版
• 学科: 医学
• 关键词: Rapidly progressive GLOMERULONEPHRITIS REMISSION induction therapy Antineutrophil cytoplasmic antibody ASSOCIATED vasculitides CYCLOPHOSPHAMIDE RITUXIMAB CORTICOSTEROIDS Plasma exchange Avacopan
• 年，卷（期）: 2018,（3）
• 页码范围: 71-83
• 页数: 13页
• 分类号: R

摘要

Renal involvement with rapidly progressive glomerulonephritis is a common manifestation of antineutrophil cytoplasmic antibody(ANCA)associated vasculitides,which is characterized by end-stage renal disease and high mortality rates in untreated and/or late referral patients.The long-term renal survival has improved dramatically since the addition of cyclophosphamide(CYC)and recently of rituximab(RTX)in association with corticosteroids in the remission induction therapeutic regimens.However,renal prognosis remains unfavorable for many patients and the mortality rate is still significantly high.In this review,we analyze the open challenges to be addressed to optimize the induction remission therapy,principally in patients with advanced kidney failure.This concern the first-line therapy(CYC or RTX)based on different parameters(estimated glomerular filtration rate at baseline,new or relapsed disease,ANCA specificity,tissue injury,safety),the role of plasma exchange and the role of new therapies.Indeed,we discuss future perspectives in induction remission therapy by reporting recent advances in new targeted therapies with particular reference to avacopan,an orally administered selective C5a receptor inhibitor.